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ABSTRACT
Objectives Improvement of skin ﬁbrosis is part of the
natural course of diffuse cutaneous systemic sclerosis
(dcSSc). Recognising those patients most likely to
improve could help tailoring clinical management and
cohort enrichment for clinical trials. In this study, we
aimed to identify predictors for improvement of skin
ﬁbrosis in patients with dcSSc.
Methods We performed a longitudinal analysis of the
European Scleroderma Trials And Research (EUSTAR)
registry including patients with dcSSc, fulﬁlling American
College of Rheumatology criteria, baseline modiﬁed
Rodnan skin score (mRSS) ≥7 and follow-up mRSS at 12
±2 months. The primary outcome was skin improvement
(decrease in mRSS of >5 points and ≥25%) at 1 year
follow-up. A respective increase in mRSS was considered
progression. Candidate predictors for skin improvement
were selected by expert opinion and logistic regression
with bootstrap validation was applied.
Results From the 919 patients included, 218 (24%)
improved and 95 (10%) progressed. Eleven candidate
predictors for skin improvement were analysed. The ﬁnal
model identiﬁed high baseline mRSS and absence of
tendon friction rubs as independent predictors of skin
improvement. The baseline mRSS was the strongest
predictor of skin improvement, independent of disease
duration. An upper threshold between 18 and 25
performed best in enriching for progressors over
regressors.
Conclusions Patients with advanced skin ﬁbrosis at
baseline and absence of tendon friction rubs are more
likely to regress in the next year than patients with
milder skin ﬁbrosis. These evidence-based data can be
implemented in clinical trial design to minimise the
inclusion of patients who would regress under standard
of care.
INTRODUCTION
Systemic sclerosis (SSc) is a highly heterogeneous
disease, making clinical management of SSc and
patient selection for clinical trials challenging. For
skin ﬁbrosis, the modiﬁed Rodnan skin score
(mRSS) is the most widely used measure in clinical
practice and it is also the most frequent primary
end point in clinical trials.1 2 Identifying predictors
of change in mRSS over time is therefore of much
interest for risk-tailored clinical management, as
well as for clinical trial design to enrich for patients
with worsening skin ﬁbrosis.3
In a recent, large-scale, observational study on
the European Scleroderma Trials And Research
(EUSTAR) database, we identiﬁed short disease dur-
ation (<15 months), joint synovitis and low base-
line mRSS (>7/51 and ≤22/51) as independent
predictors of skin progression in patients with
diffuse cutaneous SSc (dcSSc).4 This provided an
evidence-based tool for the improved identiﬁcation
of patients at risk for progressive skin involvement
and is also valuable for cohort enrichment in clin-
ical trials on skin ﬁbrosis.
While the identiﬁcation of factors predicting pro-
gression has been improved, little is known about
predictors of regression of skin ﬁbrosis in patients
with SSc. Regression of mRSS has long been identi-
ﬁed as a characteristic feature of the natural history
of skin ﬁbrosis in patients with dcSSc. Regression is
thought to occur after the early active phase of the
disease has stabilised. However, the time to peak
skin score varies widely in patients, leading to a
highly heterogeneous pattern of regressing, pro-
gressing and stable patients even in early disease
stages.5 6
From a therapeutic perspective, there is general
agreement that prevention of progression in patients
with active skin ﬁbrosis is one of the major treat-
ment goals. However, it is much less established
whether a therapeutic beneﬁt can be achieved for
patients who are already likely to show improve-
ment of skin ﬁbrosis under standard of care. In such
a population the beneﬁt/risk ratio of any treatment
would have to be accurately assessed. Therefore, in
order to identify those patients who would beneﬁt
most from therapeutic interventions, it is important
to identify patients with progressive skin ﬁbrosis,
and to be aware of patients with skin regression. For
trial design, it is important to enrich for progressive
patients, and to exclude regressing patients under
standard of care to increase the likelihood of identi-
fying treatment effects.
So far, previous attempts to identify predictors of
change in mRSS have been largely inconclusive,4
and patients recruited for clinical studies targeting
skin ﬁbrosis often show spontaneous regression of
mRSS.4 5 Thus, the objective of our study was to
provide evidence-based predictors of skin improve-
ment in patients with dcSSc using the EUSTAR
database.
METHODS
Patients and study design
The longitudinally followed EUSTAR cohort was
analysed for this observational study. The whole
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EUSTAR data set, consisting of 12 274 patients at the time of
the ﬁrst data export (20 February 2015), was considered.
The following inclusion criteria were used for cohort selec-
tion: fulﬁlment of American College of Rheumatology 1980
classiﬁcation criteria, dcSSc, mRSS ≥7 at the ﬁrst visit (baseline)
and available data for mRSS at 12±2 months follow-up.
Patients with dcSSc were identiﬁed according to LeRoy et al7
or, in case of missing values for the LeRoy criteria, by diffuse
skin involvement at any visit. The minimum mRSS ≥7 was
chosen because it reﬂects the lowest value classiﬁable as dcSSc,
thus allowing the inclusion of patients with dcSSc with less
severe to extensive skin ﬁbrosis. The 1 year follow-up has been
shown adequate for capturing signiﬁcant changes in mRSS and
is often used in clinical trials in skin ﬁbrosis in SSc.2
The clinical data in EUSTAR are prospectively collected in a
multicentre approach following a standardised protocol.8–10
Regular training courses in skin scoring are organised by
EUSTAR and all centres are advised to have the same examiner
assessing the skin score in individual patients at follow-up
visits.4 Quality indicators for data from the registry include
regular external monitoring of large centres and plausibility
checks on key items with written requests to centres for clariﬁ-
cation. Ethics approval has been obtained from the respective
local ethics committees by all participating EUSTAR centres.
Statistical analysis
The primary end point, improvement of skin ﬁbrosis, was
deﬁned as a decrease in mRSS of >5 points and ≥25% within
1 year. These thresholds were chosen according to the minimal
clinically important difference.11 Similarly, progression of skin
ﬁbrosis was deﬁned as an increase in mRSS of >5 points and
≥25% within 1 year as used previously.4 For deﬁnitions of the
clinical variables see the online supplement.
A subanalysis using receiver operating characteristic analysis
was performed with skin improvement, and, respectively, skin
progression as the state variable, in order to explore the rela-
tionship between different baseline mRSS cut-off points and the
proportion of regressors and progressors included in the cohort.
Candidate predictors for skin improvement were selected
based on nominal group technique by SSc experts (OD, YA,
OK-B, CM, RD), who were asked to suggest clinically meaning-
ful variables with face validity (see the online supplement). All
parameters suggested by the experts (see online supplementary
table S1) with <50% missing data were considered for the ana-
lysis. As a ﬁrst step, a multivariable logistic regression model
including all selected 11 parameters was run after single condi-
tional mean imputation of the data. Baseline mRSS was centred
at 7 points as all patients had baseline mRSS ≥7. Because base-
line mRSS did not behave linearly, a quadratic term for baseline
mRSS was included in the model. The Wald statistics (see online
supplementary table S3) showed that the effects were very far
from being signiﬁcant (p value >0.7) for joint contractures and
diffusing capacity of the lung for carbon monoxide ≥70%.
Thus, these parameters were excluded from further models. The
interaction between disease duration and baseline mRSS was
also tested, but proved to be insigniﬁcant, meaning that the
effect of baseline mRSS on regression of SSc did not depend on
disease duration. The model after single imputation is shown in
the online supplementary table S4. Single imputation was done
for validation as it is not possible to validate models with multi-
ply imputed data. Thus, bootstrap with 100 repetitions was
used to validate the model (see online supplementary table S5).
However, as multiple imputation provides more trustworthy
estimates and ORs than single imputation, the ﬁnal logistic
regression model from the multiply imputed data set is
presented.
The statistical analysis was performed by the biostatistician
(NG) using R V.3.1.0 (see the online supplement).
RESULTS
Study population
A total of 919 patients with dcSSc who met the inclusion cri-
teria were analysed. Of these, 218/919 (24%) patients showed
skin improvement over 1-year follow-up. The patients’ demo-
graphic and clinical characteristics are shown in table 1.
Multivariable analysis
The candidate predictors selected after nominal group technique
and exclusion of parameters with higher missing values and
ﬁnally included in the multivariable analysis are shown in box 1.
The prediction model for skin improvement after single
imputation is shown in online supplementary table S4. The
most signiﬁcant predictor was baseline mRSS (p<0.001). Other
signiﬁcant predictors were absence of tendon friction rubs and
negative Scl-70 antibodies. The performance parameters of the
model before and after validation are shown in online supple-
mentary table S5.
Multiple imputation was used to ﬁt the model and to obtain
SEs. The ﬁnal model with multiply imputed data is shown in
table 2.
High baseline mRSS remained the strongest predictor of skin
improvement (p<0.001). The model for example indicates that
the risk for regression within 12 months is more than doubled
(OR=2.316) for a patient with a baseline mRSS of 22 points, in
comparison to a patient with a baseline mRSS of 14 (all other
parameters being equal). Furthermore, absence of tendon fric-
tion rubs signiﬁcantly predicted skin improvement. Absence of
anti-Scl-70 antibodies, which was also a signiﬁcant predictor in
the model after single imputation (see online supplementary
table S3), only retained a trend in the model from the multiply
imputed data set.
Baseline mRSS as predictor of the pattern of skin change in
dcSSc over 1 year
The observation that high baseline mRSS was the strongest pre-
dictor of skin improvement complements our previous ﬁndings
indicating low baseline mRSS as an important predictor of skin
worsening.4 This was also conﬁrmed in the current cohort: the
95/919 (10%) patients with dcSSc who showed skin progression
within 1 year had lower baseline mRSS (p<0.001). Baseline
mRSS is thus a predictor of change in skin score after 1 year,
patients with lower skin scores being prone to progress and
those with higher skin scores prone to improve within the next
12 months (see online supplementary ﬁgure S1).
Having in mind the optimisation of cohort enrichment with
maximal number of progressive patients and minimal numbers
of regressive patients, we checked for the optimal mRSS cut-off
(ﬁgure 1). In this cohort, an upper baseline mRSS cut-off value
of 18 points performed best, including the highest proportion
of progressors (78.9%) and the lowest proportion of regressors
(35.3%, ﬁgure 1).
If translated into clinical study design, this suggests a baseline
mRSS between 7 and 18 as an inclusion criterion, raising ques-
tions for feasibility of recruiting patients. Thus, we next ana-
lysed the impact of higher cut-offs for upper baseline mRSS on
the proportion of progressive and regressive patients. This ana-
lysis showed that a baseline mRSS between 18 and 25 would
still allow identifying a reasonably high rate of progressors over
2 Dobrota R, et al. Ann Rheum Dis 2016;0:1–6. doi:10.1136/annrheumdis-2015-208024
Clinical and epidemiological research
group.bmj.com on May 24, 2016 - Published by http://ard.bmj.com/Downloaded from 
regressors, whereas for skin scores higher than 25 a considerable
drop of the included progressors and a dramatic increase in the
percentage of regressors was observed (table 3).
DISCUSSION
Patients with improvement of skin ﬁbrosis under standard of
care are less likely to beneﬁt from therapeutic interventions than
patients with progressive skin ﬁbrosis. In this large EUSTAR
analysis of 919 patients with dcSSc with clinically derived real
life data, we have identiﬁed parameters which can predict
improvement of skin ﬁbrosis over a 12 month observation
period, the strongest being high baseline mRSS.
To our knowledge, this is the ﬁrst report of an evidence-based
model for the prediction of skin improvement in a non-selected
cohort of patients with dcSSc. In a previous study, Steen et al
speciﬁcally focused on improvement of skin thickening in a
cohort of 278 patients with early dcSSc. In this study, independ-
ent predictors for skin improvement could not be identiﬁed
(except for D-Penicillamine use, which is however contradictory
to the negative results of the dedicated randomised controlled
trial).13–15 Potential explanations for this lack of predictors
include the lower sample size, and the higher baseline mRSS in
this study. The higher baseline mRSS might also explain the
Table 2 Final logistic regression model for prediction of skin
improvement at 1 year
Predictors Estimate SE OR p Value 95% CI
ANA positive −0.378 0.339 0.685 0.266 0.352 to 1.334
Anti-Scl70 positive −0.324 0.180 0.723 0.071 0.508 to 1.028
Tendon friction rubs −0.492 0.214 0.612 0.022 0.402 to 0.930
Proteinuria 0.294 0.292 1.341 0.315 0.756 to 2.380
Lung fibrosis 0.112 0.179 1.119 0.530 0.787 to 1.590
Disease duration
(months)
−0.001 0.001 0.999 0.287 0.997 to 1.001
Baseline mRSS 0.171 0.031 1.186 <0.001 1.115 to 1.262
Baseline mRSS2 −0.003 0.001 0.997 0.004 0.996 to 0.999
Intercept −3.233 0.538 0.039 <0.001 0.014 to 0.113
ANA, antinuclear antibodies; Anti-Scl70 antibodies, antitopoisomerase I antibodies;
mRSS, modified Rodnan skin score.
Box 1 Candidate predictors of skin improvement
selected for the analysis
Variable
▸ Baseline mRSS
▸ Disease duration
▸ ANA positive
▸ Anti-Scl70 positive
▸ Tendon friction rubs
▸ Proteinuria
▸ Conduction blocks
▸ Abnormal diastolic function
▸ Fibrosis on chest X-ray
▸ DLCO ≥70%
▸ Joint contractures
ANA, antinuclear antibodies; Anti-Scl70 antibodies,
antitopoisomerase I antibodies; DLCO, diffusing capacity of the
lung for carbon monoxide; mRSS, modiﬁed Rodnan skin score.
Table 1 Description of the study cohort at baseline (total N=919)
Age (years) 51 (40,60)
Male 199/919 (21.7)
Female 720/919 (78.3)
Disease duration (months)* 42.5 (17,104)
Short disease duration ≤36 months* 389/854 (45.6)
Raynaud’s phenomenon 898/919 (97.7)
Puffy fingers 235/390 (60.3)
Digital ulcers (ever) 396/914 (43.3)
Active digital ulcers 84/394 (21.3)
mRSS 16 (11,23)
Organ involvement
Musculoskeletal
Synovitis† 196/915 (21.4)
Joint contractures 458/916 (50.0)
Tendon friction rubs 185/914 (20.2)
Muscle weakness 294/915 (32.1)
Cardiopulmonary
Dyspnoea (NYHA)
Stage I 210/369 (56.9)
Stage II 118/369 (32.0)
Stage III 37/369 (10.0)
Stage IV 4/369 (1.1)
Conduction blocks 109/877 (12.4)
Diastolic dysfunction 165/864 (19.1)
LVEF <45% 6/318 (1.9)
Pulmonary hypertension by Echo 167/868 (19.2)
Lung fibrosis on chest X-ray 389/849 (45.8)
Lung fibrosis on HRCT 163/287 (56.8)
FVC <80% 127/362 (35.1)
TLC <80% 80/245 (32.7)
DLCO <70% 357/621 (57.5)
Gastrointestinal
Oesophageal symptoms 625/917 (68.2)
Stomach symptoms 257/916 (28.1)
Intestinal symptoms 222/917 (24.2)
Renal crisis 23/915 (2.5)
Laboratory markers
ANA 859/908 (94.6)
ACA 76/872 (8.7)
Anti-Scl70 524/886 (59.1)
Anti-U1RNP 16/285 (5.6)
Anti-RNA polymerase III 18/215 (8.4)
CK elevation 112/879 (12.7)
Proteinuria 74/887 (8.3)
ESR>25 mm/1 h 134/368 (36.4)
CRP elevation 107/374 (28.6)
Active disease (VAI >3)12 146/337 (43.3)
Immunosuppressive treatment 334/436 (76.6)
For nominal variables, the absolute and relative frequencies are shown: n/total valid
cases (%). Continuous variables are described as median and 1st, 3rd quartiles (Q1, Q3).
*Disease duration was calculated as difference between the date of the baseline visit and
the date of the first non-Raynaud’s symptom of the disease, as reported by the patients.
†Joint synovitis was defined as swelling of the joints as judged by the treating physician.
ACA, anticentromere antibodies; ANA, antinuclear antibodies; Anti-Scl70 antibodies,
antitopoisomerase I antibodies; CK, creatine kinase; CRP, C reactive protein; DLCO,
diffusing capacity of the lung for carbon monoxide; Echo, echocardiography; ESR,
erythrocyte sedimentation rate; FVC, forced vital capacity; HRCT, high resolution
computer tomography; LVEF, left ventricular ejection fraction; mRSS, modified Rodnan
skin score; NYHA, New York Heart Association; RNP, ribonucleoprotein; TLC, total lung
capacity; VAI, Valentini Activity Index.
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higher rate of improvers in this study (63% vs 22% in our
EUSTAR analysis).
A key message resulting from our study is the important role
of baseline mRSS to predict either progression or regression of
skin ﬁbrosis. This also supports our previous EUSTAR analysis
on worsening of skin ﬁbrosis.4 In a pooled analysis of patients
with dcSSc from seven multicentre clinical trials, mRSS at base-
line had a weak negative correlation with any change in mRSS.6
Furthermore, in a recent analysis from the Canadian cohort,
baseline mRSS was the only baseline parameter signiﬁcantly
associated with a signiﬁcant change in mRSS at follow-up
(deﬁned as difference in 8 points).16 These data underline the
value of mRSS for cohort enrichment in clinical trials. Our
study also provides evidence-derived data on different thresh-
olds of baseline mRSS and their performance to enrich for pro-
gressors over regressors in clinical trials (table 3). Thus, the
optimal baseline mRSS cut-off for a speciﬁc study can be chosen
from these data taking into account feasibility versus optimised
cohort enrichment.
Another important aspect to consider is the natural regression
to the mean phenomenon: the more extreme the skin score
values in the study population at baseline, the more likely they
are to decrease towards the mean at follow-up, thus not neces-
sarily reﬂecting treatment response. The regression to the mean
is most likely the statistical effect that explains the selection of
baseline mRSS as a strong predictor of worsening and regres-
sion, respectively.
While our study addresses a very large SSc cohort with mul-
tiple data quality controls and external data monitoring, it also
has several limitations. It has the natural drawbacks of registry
data, such as missing data. However, we have addressed this
issue by applying acknowledged imputation methods to com-
pensate for missing data. Nonetheless, some of the candidate
predictors had too much missing data which did not allow a
trustable imputation, hence we could not include them in the
analysis. The inclusion threshold of mRSS>7 aimed at identify-
ing patients with true dcSSc with minimum involvement of
distal upper extremities, but is, nonetheless, somewhat arbitrary.
Our data also have to be conﬁrmed in other cohorts with differ-
ent baseline characteristics, for example, with higher prevalence
of anti-RNA polymerase III antibodies. Additional information
from in-between visits (eg, at 3 months, 6 months) as well as
health assessment questionnaire data17 could bring additional
valuable information on the course of skin ﬁbrosis. Moreover, it
has to be mentioned that the ﬁnal prediction model only
explains about 16% of the variation in skin ﬁbrosis regression
(see online supplementary table S4), indicating that other yet
unknown factors such as, for example, biomarkers have an
important role in determining the improvement of skin ﬁbrosis
in dcSSc. Further, modiﬁcations on how to measure the mRSS
(eg, averaging vs maximising skin thickness over a certain skin
area) will have great impact on the speciﬁc baseline mRSS
values and have to be considered when these data are applied to
clinical trials.
In conclusion, our study provides novel evidence-based data
for cohort enrichment in clinical trials on skin ﬁbrosis in patients
with dcSSc. These data further support a lower baseline mRSS as
inclusion criteria to optimise the ratio of progressors over regres-
sors for recruitment into clinical trials. Other signiﬁcant predic-
tors of improvement with potential application to clinical trials
resulting from these data are absence of tendon friction rubs,
and, potentially, negativity for anti-Scl70 antibodies.
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